VolitionRx (VNRX) Faces NYSE American Compliance Notice Over Stockholders’ Equity Shortfall

Epigenetics firm receives compliance notice from NYSE American

VolitionRx Limited, a multi‑national epigenetics company, is responding to a notice from NYSE American that it does not meet the exchange’s continued listing standards for minimum stockholders’ equity. The exchange notifies the company on Feb. 6, 2026 and VolitionRx publicly discloses the notice on Feb. 9, 2026. The message signals an administrative review rather than an immediate trading suspension, and the company continues its operations and market communication while preparing a formal response.

NYSE American cites minimum equity thresholds, plan deadline, possible delisting

NYSE American informs VolitionRx that it fails to satisfy Section 1003(a)(i), (ii) and (iii) of the Company Guide, which set graduated minimum stockholders’ equity requirements of $2.0 million, $4.0 million and $6.0 million depending on recent operating results. The exchange also states VolitionRx is not eligible for any exemption under Section 1003(a), including one available to companies with total market capitalisation above $50 million. The company must submit a written plan by March 8, 2026 describing steps taken or planned to regain compliance by Aug. 6, 2027. If NYSE American accepts the plan, VolitionRx will face periodic reviews and quarterly monitoring; failure to file an acceptable plan, show progress consistent with an accepted plan, or achieve compliance by the deadline could lead the exchange to initiate delisting proceedings. VolitionRx retains the right to appeal any staff delisting determination under Section 1010 and Part 12 of the Company Guide.

Listing status, trading designation and corporate continuity

The notice has no immediate effect on the listing of VolitionRx’s common stock, which continues to trade on NYSE American under the symbol VNRX and carries a “.BC” designation to indicate below‑compliance status. The exchange’s action is procedural and meant to ensure companies meet financial thresholds; it does not alter the company’s ongoing research, clinical programs or workforce.

Company emphasises focus on research and shareholder communications

VolitionRx stresses that day‑to‑day operations, research programmes and corporate communications continue uninterrupted while it engages with NYSE American. The company says it will submit the required plan and keep shareholders informed as it works to address the equity deficiency and satisfy the exchange’s continued listing standards.